SS-31
SS-31, also written SS 31, is supplied by White Label Peptides as a lyophilised powder in multi-dose vials, for laboratory and research use, to business buyers only. It sits in our longevity category. Every batch is verified by HPLC and ships with its own Certificate of Analysis.
| Compound | SS-31 |
|---|---|
| Also known as | Elamipretide |
| Synonyms | Elamipretide |
| Classification | Mitochondrial Function & Cellular Energy Research Peptide |
| Peptide type | Mitochondrial-Targeted Tetrapeptide |
| Molecular formula | C32H49N9O5 |
| Molecular weight | Approximately 639.8 g/mol |
| Sequence | D-Arg-dimethylTyr-Lys-Phe-NH2 |
| Form | Lyophilised peptide powder - Multi-dose research vials - Injectable research format |
| Appearance | White to off-white lyophilised powder prior to reconstitution |
| Presentation | Vials: 10 mg |
| Reconstitution | Typically reconstituted using: Bacteriostatic water - Sterile laboratory-grade water |
| Storage | Store refrigerated at 2-8°C in a cool, dry environment away from direct sunlight. Long-term storage may require freezing conditions prior to reconstitution. |
Specification data is provided for identification and procurement. It is not dosing guidance and it is not a claim of any effect.
Evidence and status
- Lab work
- Animal studies
- Human studies
- Approved label
Reviewed 2026-09-02. Regulatory status is stated for procurement and varies by market. It is not legal advice.
Research
What the published literature examined
The molecule went through a full regulatory programme in one narrow indication. FDA brought the application to the Cardiovascular and Renal Drugs Advisory Committee on 10 October 2024 and granted accelerated approval in September 2025, the first approval for Barth syndrome, an ultra-rare genetic disorder. The approval rests on knee extensor muscle strength measured by hand-held dynamometry, used as an intermediate clinical endpoint rather than as a demonstration of clinical benefit. A confirmatory randomised trial is running as a condition of that approval.
What is not established
Confirmed clinical benefit, which is precisely what accelerated approval defers. The endpoint the approval rests on is an intermediate one, and the trial required to confirm benefit is still running. There is no approval for anyone under 30 kg. And nothing in the approval addresses any use outside Barth syndrome: the regulatory record establishes an effect on muscle strength in one ultra-rare mitochondrial disorder, and establishes nothing about the mitochondrial and longevity uses this compound is generally sold for.
What distinguishes SS-31
It is the newest approval in this catalogue and by far the narrowest, and the gap between those two facts is the whole point. Sellers of SS-31 rarely mention that the molecule is now an approved drug; the ones who do rarely mention that the approval covers an ultra-rare genetic disorder, in patients over 30 kg, on an intermediate endpoint, with benefit still to be confirmed. An approval is a fact about one indication and one population, not a general endorsement of a molecule, and this compound is the clearest example of that distinction in the range.
Sources
- US FDA. FDA grants accelerated approval to first treatment for Barth syndrome, September 2025
- US FDA. NDA 215244 accelerated approval letter, Stealth BioTherapeutics Inc.
- US FDA. Briefing document, NDA 215244, Cardiovascular and Renal Drugs Advisory Committee, 10 October 2024
- US FDA. NDA 215244 integrated review
- ClinicalTrials.gov. NCT07531251, 4TAZPower, clinical trial in patients with Barth syndrome
This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.
Specification
About this compound
The specification below is the batch-independent data. Purity and analysis date vary by batch, so they appear on the certificate issued with your order rather than on this page.
What this compound is
SS-31 in supply terms
SS-31, also supplied under the name Elamipretide, is a synthetic tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2. Two features distinguish its chemistry from a standard amino acid chain: a D-amino acid at the first position, which resists the enzymes that break down conventional L-amino acid peptides, and a C-terminal amide cap in place of a free carboxylic acid. The molecular formula is C32H49N9O5, with a molecular weight near 639.8 g/mol. The site lists it as a mitochondrial-targeted tetrapeptide, a category label describing the class of short, charge-modified peptides grouped together on this catalogue rather than a claim about the compound. It is supplied as a lyophilised powder in multi-dose vials at a 50mg fill weight, in an injectable research format, and reconstitutes with bacteriostatic water or sterile laboratory-grade water. Storage is 2-8C, out of direct sunlight, with freezing suitable for extended holding before reconstitution. Because SS-31 is one of the smaller-formula peptides in this catalogue by molecular weight, buyers should check whether a quoted price reflects the 50mg vial fill directly or an unspecified concentration, and confirm HPLC purity data accompanies each batch on the Certificate of Analysis.
This section describes the compound as a material. It makes no claim about any effect and is not guidance on use.
What varies by batch
The page identifies the compound. The certificate records the batch.
Purity, method, analysis date and issuing party belong on the batch record rather than in page copy.
| Send the volume you need for SS-31 and your delivery country. We will quote against it. | Request pricing |
Same category
Also in Longevity
| Compound | Identifier | Presentation |
|---|---|---|
| 5-Amino-1MQ | 42464-96-0 (commonly supplied a... | Vials: 50 mg. Pre-filled pens: ... |
| Epithalon | C14H22N4O9 | Vials: 10 mg. Pre-filled pens: ... |
| FOXO4-DRI | 2460055-10-9 | Vials: 10 mg. Pre-filled pens: ... |
| MOTS-c | C101H152N28O22S2 | Vials: 10 mg. Pre-filled pens: ... |
| NAD+ | C21H27N7O14P2 | Vials: 500 mg. Pre-filled pens:... |
| Thymosin Alpha-1 (TA) | 62304-98-7 | Vials: 5 mg, 10 mg. Pre-filled ... |
Questions
Supply, answered
Is SS-31 available for private label?
Yes. It can be supplied under your own brand on the vial and the carton, with the Certificate of Analysis issued under your product name.
What is the minimum order quantity?
Set for this compound specifically and confirmed at the enquiry stage, before you commit.
What purity is supplied?
98 percent or higher, verified by HPLC. The certificate issued with your batch carries the actual figure for that batch.
How is it shipped?
As lyophilised powder in multi-dose vials, packed for transit. Delivery in 5 to 7 days once the batch is released.
We already buy SS-31. Can you quote against our current volume?
Yes. Send the volume and the delivery country. Pricing is tiered per compound, so the quote reflects what you buy rather than a list price.
Can you supply SS-31 as a second source?
Yes. Terms are agreed per compound, so you can add SS-31 without moving anything else you buy elsewhere.
Request pricing for SS-31
Indicative volume and delivery country is enough to start. We reply within one working day.